<abstract><p>Hepatitis C virus genotype 2 (HCV-2) slow responders poorly respond to 24 weeks of peginterferon (Peg-IFN) plus ribavirin (RBV). We evaluated the efficacy of extended 48-week regimen and the role of interleukin-28B (IL-28B) genotype in this clinical setting. Treatment-na&#x000ef;ve HCV-2 patients not achieving rapid virologic response (RVR) by Peg-IFN alfa-2a 180&#x02009;&#x003bc;g/week plus weight-based RBV (1,000&#x02013;1,200&#x02009;mg/day, cutoff body weight of 75&#x02009;kg) were randomly assigned to receive a total duration of 48 (n&#x02009;=&#x02009;94) or 24 (n&#x02009;=&#x02009;93) weeks of therapy. The primary endpoint was sustained virologic response (SVR). Baseline patient characteristics to predict SVR were analyzed. Patients receiving 48 weeks of treatment had a greater SVR rate than those receiving 24 weeks of treatment (70.2% versus 46.2%, <italic>P</italic>&#x02009;=&#x02009;0.001). Compared to patients treated for 24 weeks, the SVR rate in those treated for 48 weeks increased by 10.9% [95% CI: &#x02212;5.9% to 27.7%] and 65.6% [95% CI: 44.5% to 86.7%] if they had IL-28B rs8099917 TT genotype, and GT/GG genotype, respectively (interaction <italic>P</italic>&#x02009;=&#x02009;0.002). In conclusion, 48-week treatment with Peg-IFN plus weight-based RBV provides a greater SVR rate than 24-week treatment in treatment-na&#x000ef;ve HCV-2 patients with unfavorable IL-28B genotypes who fail to achieve RVR.</p></abstract><sec disp-level="1" sec-type="results"><title>Results</title><sec disp-level="2"><title>Patient Characteristics</title><p>Among the 190 patients not achieving RVR by Peg-IFN plus weight-based RBV therapy, 187 were allocated to a total duration of 48-week (n&#x02009;=&#x02009;94) or 24-week (n&#x02009;=&#x02009;93) therapy. Seventy-four (78.7%) and 80 (86.0%) patients assigned to 48-week and 24-week therapies completed treatment, and 87 (92.6%) and 88 (94.6%) patients completed 24 weeks of post-treatment follow-up to assess the SVR rates (<xref ref-type="fig" rid="f1">Fig. 1</xref>). The baseline patient characteristics were comparable between the two arms (<xref ref-type="table" rid="t1">Table 1</xref>).They were slim with an average BMI of 26.3&#x02013;26.7&#x02009;kg/m<sup>2</sup>.Most of the patients had high baseline viral load (62&#x02013;65%) and favorable IL-28B rs8099917 genotype (71&#x02013;74%), and were infected with 2a subtype (68&#x02013;71%). With regard to aspartate aminotransferase (AST)-to-platelet ratio index (APRI) score, 23.7&#x02013;27.7% patients had a score of &#x0003e;2.00.</p></sec><sec disp-level="2"><title>Efficacy</title><p>The early virologic response (EVR) (91.5% versus 88.2%, RD: 3.3% [95% CI: &#x02212;5.3% to 12.0%]; <italic>P</italic>&#x02009;=&#x02009;0.45) and the end-of-treatment virologic response (ETVR) (88.3% versus 80.6%, RD: 7.7% [95% CI: &#x02212;2.7% to 18.0%]; <italic>P</italic>&#x02009;=&#x02009;0.15) rates were comparable between the treatment arms. The SVR rate of 48-week treatment was greater than 24-week treatment (70.2% versus 46.2%, RD: 24.0% [95% CI: 10.3% to 37.7%]; <italic>P</italic>&#x02009;=&#x02009;0.001) (<xref ref-type="table" rid="t2">Table 2</xref>). Patients with RBV cumulative exposure &#x0003c;60% had lower SVR rates than those with RBV cumulative exposure &#x02265;60% in 48-week arm (77.6% versus 38.9%, <italic>P&#x02009;</italic>=&#x02009;0.003) and 24-week arm (53.8% versus 6.7%, <italic>P&#x02009;</italic>=&#x02009;0.001), respectively.</p></sec><sec disp-level="2"><title>Subgroup Analyses for Prespecified Factors</title><p>Differences of SVR rates between patients receiving 48 and 24 weeks of treatment did not vary by baseline viral load (interaction <italic>P</italic>&#x02009;=&#x02009;0.82), subgenotype (interaction <italic>P</italic>&#x02009;=&#x02009;0.89), age (interaction <italic>P</italic>&#x02009;=&#x02009;0.73), sex (interaction <italic>P</italic>&#x02009;=&#x02009;0.94), body mass index (BMI) (interaction <italic>P</italic>&#x02009;=&#x02009;0.26), APRI score (interaction <italic>P</italic>&#x02009;=&#x02009;0.83) or RBV cumulative exposure (interaction <italic>P&#x02009;</italic>=&#x02009;0.48) (<xref ref-type="table" rid="t3">Table 3</xref>). Compared to patients with favorable IL-28B rs8099917 genotype (69.2% versus 58.3%, risk difference (RD): 10.9% [95% CI: &#x02212;5.9% to 27.7%]), patients with unfavorable IL-28B rs8099917 genotypes receiving 48-week therapy achieved a greater SVR rate than 24-week therapy (73.9% versus 8.3%, RD: 65.6% [95% CI: 44.5% to 86.7%]; interaction <italic>P</italic>&#x02009;=&#x02009;0.002). The SVR rates of 48-week and 24-week treatment were similar when the patients had BMI &#x0003e;30&#x02009;kg/m<sup>2</sup> (52.6% versus 50.0%, RD: 2.6% [95% CI: &#x02212;33.5% to 38.8%]).</p></sec><sec disp-level="2"><title>Safety</title><p>The constitutional and laboratory adverse events (AEs) were similar between the two arms (<xref ref-type="table" rid="t4">Table 4</xref>). Four and 3 patients in 48-week and 24-week arms had serious AEs during treatment (4.3% versus 3.2%, RD: 1.1% [95% CI: &#x02212;4.4% to 6.5%]. The AE-related withdrawal rates were 11.7% in 48-week treatment arm and 6.5% in 24-week treatment arm (RD: 5.2% [95% CI: 2.9% to 13.5%]). The rates of anemia beyond week 6 of treatment were 44.7% and 34.4% (RD: 10.3% [95% CI: &#x02212;3.7% to 24.2%].</p></sec></sec><floats-group><fig id="f1"><label>Figure 1</label><caption><title>Study Flow Diagram. Peg-IFN: peginterferon, RBV: ribavirin; RVR: rapid virologic response, AE: adverse event.</title></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="srep11710-f1" /></fig><fig id="f2"><label>Figure 2</label><caption><title>Study Design. Peg-IFN: peginterferon, RBV: ribavirin; RVR: rapid virologic response, ETV: early virologic response, ETVR: end-of-treatment virologic response, SVR: sustained virologic response, SD: weight-based dosing, W: week.</title></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="srep11710-f2" /></fig><table-wrap position="float" id="t1"><label>Table 1</label><caption><title>Baseline Patient Characteristics<xref ref-type="fn" rid="t1-fn1">*</xref>.</title></caption><table frame="hsides" rules="groups" border="1"><colgroup><col align="left" /><col align="char" char="(" /><col align="char" char="(" /></colgroup><thead valign="bottom"><tr><th align="left" valign="top" charoff="50">Characteristics</th><th align="center" valign="top" char="(" charoff="50">SD48W, N&#x02009;=&#x02009;94</th><th align="center" valign="top" char="(" charoff="50">SD24W, N&#x02009;=&#x02009;93</th></tr></thead><tbody valign="top"><tr><td align="left" valign="top" charoff="50">Mean age (SD), y</td><td align="char" valign="top" char="(" charoff="50">56 (12)</td><td align="char" valign="top" char="(" charoff="50">56 (13)</td></tr><tr><td align="left" valign="top" charoff="50">Age &#x0003e;50 y</td><td align="char" valign="top" char="(" charoff="50">64 (68)</td><td align="char" valign="top" char="(" charoff="50">59 (63)</td></tr><tr><td align="left" valign="top" charoff="50">Male sex</td><td align="char" valign="top" char="(" charoff="50">51 (54)</td><td align="char" valign="top" char="(" charoff="50">52 (56)</td></tr><tr><td align="left" valign="top" charoff="50">Mean weight (SD), kg</td><td align="char" valign="top" char="(" charoff="50">69 (13)</td><td align="char" valign="top" char="(" charoff="50">69 (11)</td></tr><tr><td align="left" valign="top" charoff="50">Mean BMI (SD), kg/m<sup>2</sup></td><td align="char" valign="top" char="(" charoff="50">26.7 (4.5)</td><td align="char" valign="top" char="(" charoff="50">26.3 (3.5)</td></tr><tr><td colspan="3" align="left" valign="top" charoff="50">BMI (SD), kg/m<sup>2</sup></td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;&#x02264;27.0</td><td align="char" valign="top" char="(" charoff="50">54 (57.4)</td><td align="char" valign="top" char="(" charoff="50">52 (55.9)</td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;27.1&#x02013;30.0</td><td align="char" valign="top" char="(" charoff="50">21 (22.3)</td><td align="char" valign="top" char="(" charoff="50">29 (31.2)</td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;&#x0003e;30.0</td><td align="char" valign="top" char="(" charoff="50">19 (20.2)</td><td align="char" valign="top" char="(" charoff="50">12 (12.9)</td></tr><tr><td align="left" valign="top" charoff="50">Mean hemoglobin level (SD), g/dL</td><td align="char" valign="top" char="(" charoff="50">14.4 (1.5)</td><td align="char" valign="top" char="(" charoff="50">14.7 (1.4)</td></tr><tr><td align="left" valign="top" charoff="50">Mean white cell count (SD), 10<sup>9</sup>cells/L</td><td align="char" valign="top" char="(" charoff="50">5.6 (1.4)</td><td align="char" valign="top" char="(" charoff="50">5.8 (1.5)</td></tr><tr><td align="left" valign="top" charoff="50">Mean neutrophil count (SD), 10<sup>9</sup>cells/L</td><td align="char" valign="top" char="(" charoff="50">3.0 (1.1)</td><td align="char" valign="top" char="(" charoff="50">3.2 (1.2)</td></tr><tr><td align="left" valign="top" charoff="50">Mean platelet count (SD), 10<sup>9</sup>cells/L</td><td align="char" valign="top" char="(" charoff="50">175 (61)</td><td align="char" valign="top" char="(" charoff="50">182 (64)</td></tr><tr><td align="left" valign="top" charoff="50">Mean albumin level (SD), g/dL</td><td align="char" valign="top" char="(" charoff="50">4.3 (0.4)</td><td align="char" valign="top" char="(" charoff="50">4.3 (0.3)</td></tr><tr><td align="left" valign="top" charoff="50">Mean total bilirubin level (SD), mg/dL</td><td align="char" valign="top" char="(" charoff="50">1.0 (0.4)</td><td align="char" valign="top" char="(" charoff="50">1.0 (0.5)</td></tr><tr><td align="left" valign="top" charoff="50">Mean AST quotient (SD), ULN</td><td align="char" valign="top" char="(" charoff="50">2.2 (1.2)</td><td align="char" valign="top" char="(" charoff="50">2.3 (1.1)</td></tr><tr><td align="left" valign="top" charoff="50">Mean ALT quotient (SD), ULN</td><td align="char" valign="top" char="(" charoff="50">3.4 (2.1)</td><td align="char" valign="top" char="(" charoff="50">3.8 (2.3)</td></tr><tr><td align="left" valign="top" charoff="50">Mean APRI score (SD)</td><td align="char" valign="top" char="(" charoff="50">1.5 (1.0)</td><td align="char" valign="top" char="(" charoff="50">1.5 (1.1)</td></tr><tr><td colspan="3" align="left" valign="top" charoff="50">APRI score</td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;&#x02264;1.50</td><td align="char" valign="top" char="(" charoff="50">56 (59.6)</td><td align="char" valign="top" char="(" charoff="50">50 (53.8)</td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;1.51&#x02013;2.0</td><td align="char" valign="top" char="(" charoff="50">12 (12.7)</td><td align="char" valign="top" char="(" charoff="50">21 (22.5)</td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;&#x0003e;2.00</td><td align="char" valign="top" char="(" charoff="50">26 (27.7)</td><td align="char" valign="top" char="(" charoff="50">22 (23.7)</td></tr><tr><td align="left" valign="top" charoff="50">Mean HCV RNA level (SD), log<sub>10</sub> IU/mL</td><td align="char" valign="top" char="(" charoff="50">6.0 (0.9)</td><td align="char" valign="top" char="(" charoff="50">6.0 (0.6)</td></tr><tr><td colspan="3" align="left" valign="top" charoff="50">HCV RNA level, IU/mL</td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;&#x02264;800,000</td><td align="char" valign="top" char="(" charoff="50">33 (35)</td><td align="char" valign="top" char="(" charoff="50">35 (38)</td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;&#x0003e;800,000</td><td align="char" valign="top" char="(" charoff="50">61 (65)</td><td align="char" valign="top" char="(" charoff="50">58 (62)</td></tr><tr><td colspan="3" align="left" valign="top" charoff="50">Subgenotype</td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;2a</td><td align="char" valign="top" char="(" charoff="50">64 (68)</td><td align="char" valign="top" char="(" charoff="50">66 (71)</td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;2b</td><td align="char" valign="top" char="(" charoff="50">24 (26)</td><td align="char" valign="top" char="(" charoff="50">20 (22)</td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;2a&#x02009;+&#x02009;2b</td><td align="char" valign="top" char="(" charoff="50">6 (6)</td><td align="char" valign="top" char="(" charoff="50">7 (8)</td></tr><tr><td colspan="3" align="left" valign="top" charoff="50">IL-28B rs8099917 genotype<xref ref-type="fn" rid="t1-fn2">&#x02020;</xref></td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;TT</td><td align="char" valign="top" char="(" charoff="50">65 (74)</td><td align="char" valign="top" char="(" charoff="50">60 (71)</td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;GT and GG</td><td align="char" valign="top" char="(" charoff="50">23 (26)</td><td align="char" valign="top" char="(" charoff="50">24 (29)</td></tr></tbody></table><table-wrap-foot><fn id="t1-fn1"><p>SD: standard deviation, BMI: body mass index, AST: aspartate aminotransferase, ALT: alanine aminotransferase, ULN: upper limit of normal, APRI: aspartate aminotransferase to platelet ratio index, HCV: hepatitis C virus, IU: international unit, IL: interleukin, SD48W: 48 weeks of peginterferon alfa-2a plus weight-based ribavirin, SD24W: 24 weeks of peginterferon alfa-2a plus weight-based ribavirin.</p></fn><fn id="t1-fn2"><p><sup>*</sup>Values are numbers (percentages) unless otherwise indicated.</p></fn><fn id="t1-fn3"><p><sup>&#x02020;</sup>Available number of patients (%) for analysis: 88 (94%) and 84 (90%) in SD48W and SD24W arms, respectively.</p></fn></table-wrap-foot></table-wrap><table-wrap position="float" id="t2"><label>Table 2</label><caption><title>On-treatment and Off-treatment Virologic Responses.</title></caption><table frame="hsides" rules="groups" border="1"><colgroup><col align="left" /><col align="center" /><col align="center" /><col align="center" /><col align="center" /></colgroup><thead valign="bottom"><tr><th align="left" valign="top" charoff="50">Variable</th><th align="center" valign="top" charoff="50">SD48W, n/N (%)</th><th align="center" valign="top" charoff="50">SD24W, n/N (%)</th><th align="center" valign="top" charoff="50">RD (95% CI)</th><th align="center" valign="top" charoff="50"><italic>P</italic> value<xref ref-type="fn" rid="t2-fn1">*</xref></th></tr></thead><tbody valign="top"><tr><td colspan="5" align="left" valign="top" charoff="50">On-treatment virologic response</td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;EVR</td><td align="center" valign="top" charoff="50">86/94 (91.5)</td><td align="center" valign="top" charoff="50">82/93 (88.2)</td><td align="center" valign="top" charoff="50">3.3 (&#x02212;5.3 to 12.0)</td><td align="center" valign="top" charoff="50">0.45</td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;ETVR</td><td align="center" valign="top" charoff="50">83/94 (88.3)</td><td align="center" valign="top" charoff="50">75/93 (80.6)</td><td align="center" valign="top" charoff="50">7.7 (&#x02212;2.7 to 18.0)</td><td align="center" valign="top" charoff="50">0.15</td></tr><tr><td colspan="5" align="left" valign="top" charoff="50">Virologic outcome</td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;SVR<xref ref-type="fn" rid="t2-fn2">&#x02020;</xref></td><td align="center" valign="top" charoff="50">66/94 (70.2)</td><td align="center" valign="top" charoff="50">43/93 (46.2)</td><td align="center" valign="top" charoff="50">24.0 (10.3 to 37.7)</td><td align="center" valign="top" charoff="50">0.001</td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;Non-SVR</td><td align="center" valign="top" charoff="50">28/94 (29.8)</td><td align="center" valign="top" charoff="50">50/93 (53.8)</td><td align="center" valign="top" charoff="50">&#x000a0;</td><td align="center" valign="top" charoff="50">&#x000a0;</td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;Relapse</td><td align="center" valign="top" charoff="50">12/94 (12.8)</td><td align="center" valign="top" charoff="50">28/93 (30.1)</td><td align="center" valign="top" charoff="50">&#x000a0;</td><td align="center" valign="top" charoff="50">&#x000a0;</td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;Null-response<xref ref-type="fn" rid="t2-fn3">&#x02021;</xref></td><td align="center" valign="top" charoff="50">9/94 (9.6)</td><td align="center" valign="top" charoff="50">12/93 (12.9)</td><td align="center" valign="top" charoff="50">&#x000a0;</td><td align="center" valign="top" charoff="50">&#x000a0;</td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;Viral breakthrough<xref ref-type="fn" rid="t2-fn4">&#x000a7;</xref></td><td align="center" valign="top" charoff="50">2/94 (2.1)</td><td align="center" valign="top" charoff="50">5/93 (5.4)</td><td align="center" valign="top" charoff="50">&#x000a0;</td><td align="center" valign="top" charoff="50">&#x000a0;</td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;Undetermined<xref ref-type="fn" rid="t2-fn5">||</xref></td><td align="center" valign="top" charoff="50">5/94 (5.3)</td><td align="center" valign="top" charoff="50">5/93 (5.4)</td><td align="center" valign="top" charoff="50">&#x000a0;</td><td align="center" valign="top" charoff="50">&#x000a0;</td></tr></tbody></table><table-wrap-foot><fn id="t2-fn1"><p>RD; risk reduction, EVR: early virologic response, ETVR: end-of-treatment virologic response, SVR: sustained virologic response, CI: confidence interval.</p></fn><fn id="t2-fn2"><p><sup>*</sup>P values were obtained by Wald asymptotic test.</p></fn><fn id="t2-fn3"><p><sup>&#x02020;</sup>Patients who were lost to 24-week follow-up, were null-responsive to treatment, or had viral breakthrough or relapsed after treatment were considered failure to achieve SVR.</p></fn><fn id="t2-fn4"><p><sup>&#x02021;</sup>SD48W arm: 5 patients failed to achieve EVR; 4 patients achieved EVR but remained viremic at week 24 of treatment. SD24W arm: 7 patients failed to achieve ETR; 5 patients achieved EVR but remained viremic at week 24 of treatment.</p></fn><fn id="t2-fn5"><p><sup>&#x000a7;</sup>SD48W arm: 2 patients had viral breakthrough at week 48 of treatment. SD24W arm: 5 patients had viral breakthrough at week 24 of treatment.</p></fn><fn id="t2-fn6"><p><sup>||</sup>All patients lost to 24-week post-treatment follow-up, and all had undetectable HCV RNA level at the time of treatment discontinuation. SD48W arm: 3 completed 48 weeks of treatment, and 2 prematurely discontinued treatment at weeks 36 and 40 due to serious adverse events. SD24W arm: 2 completed 24 weeks of treatment, 2 prematurely discontinued treatment at weeks 12 and 16 due to serious adverse events and 1 prematurely discontinued treatment at week 12 due to constitutional adverse event.</p></fn></table-wrap-foot></table-wrap><table-wrap position="float" id="t3"><label>Table 3</label><caption><title>Subgroup Analyses of Prespecified Factors for SVR.</title></caption><table frame="hsides" rules="groups" border="1"><colgroup><col align="left" /><col align="center" /><col align="center" /><col align="center" /><col align="center" /></colgroup><thead valign="bottom"><tr><th align="left" valign="top" charoff="50">Variable</th><th align="center" valign="top" charoff="50">SD48W, n/N (%)</th><th align="center" valign="top" charoff="50">SD24W, n/N (%)</th><th align="center" valign="top" charoff="50">RD (95% CI)</th><th align="center" valign="top" charoff="50"><italic>P</italic>value for interaction<xref ref-type="fn" rid="t3-fn1">*</xref></th></tr></thead><tbody valign="top"><tr><td align="left" valign="top" charoff="50">Baseline viral load</td><td align="center" valign="top" charoff="50">&#x000a0;</td><td align="center" valign="top" charoff="50">&#x000a0;</td><td align="center" valign="top" charoff="50">&#x000a0;</td><td align="center" valign="top" charoff="50">0.82</td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;&#x02264;800,000 IU/mL</td><td align="center" valign="top" charoff="50">27/33 (81.8)</td><td align="center" valign="top" charoff="50">21/35 (60.0)</td><td align="center" valign="top" charoff="50">21.8 (0.9 to 42.7)</td><td align="center" valign="top" charoff="50">&#x000a0;</td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;&#x0003e;800,000 IU/mL</td><td align="center" valign="top" charoff="50">39/61 (63.9)</td><td align="center" valign="top" charoff="50">22/58 (37.9)</td><td align="center" valign="top" charoff="50">26.0 (8.7 to 43.3)</td><td align="center" valign="top" charoff="50">&#x000a0;</td></tr><tr><td align="left" valign="top" charoff="50">Subgenotype</td><td align="center" valign="top" charoff="50">&#x000a0;</td><td align="center" valign="top" charoff="50">&#x000a0;</td><td align="center" valign="top" charoff="50">&#x000a0;</td><td align="center" valign="top" charoff="50">0.89</td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;2a</td><td align="center" valign="top" charoff="50">44/64 (68.8)</td><td align="center" valign="top" charoff="50">31/66 (45.5)</td><td align="center" valign="top" charoff="50">21.8 (5.2 to 38.3)</td><td align="center" valign="top" charoff="50">&#x000a0;</td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;2b</td><td align="center" valign="top" charoff="50">18/24 (75.0)</td><td align="center" valign="top" charoff="50">10/20 (50.0)</td><td align="center" valign="top" charoff="50">25.0 (&#x02212;2.9 to 52.9)</td><td align="center" valign="top" charoff="50">&#x000a0;</td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;2a+2b</td><td align="center" valign="top" charoff="50">4/6 (67.7)</td><td align="center" valign="top" charoff="50">3/7 (42.9)</td><td align="center" valign="top" charoff="50">23.8 (&#x02212;28.8 to 76.4)</td><td align="center" valign="top" charoff="50">&#x000a0;</td></tr><tr><td align="left" valign="top" charoff="50">IL-28B rs8099917 genotype<xref ref-type="fn" rid="t3-fn2">&#x02020;</xref></td><td align="center" valign="top" charoff="50">&#x000a0;</td><td align="center" valign="top" charoff="50">&#x000a0;</td><td align="center" valign="top" charoff="50">&#x000a0;</td><td align="center" valign="top" charoff="50">0.002</td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;TT</td><td align="center" valign="top" charoff="50">45/65 (69.2)</td><td align="center" valign="top" charoff="50">35/60 (58.3)</td><td align="center" valign="top" charoff="50">10.9 (&#x02212;5.9 to 27.7)</td><td align="center" valign="top" charoff="50">&#x000a0;</td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;GT and GG</td><td align="center" valign="top" charoff="50">17/23 (73.9)</td><td align="center" valign="top" charoff="50">2/24 (8.3)</td><td align="center" valign="top" charoff="50">65.6 (44.5 to 86.7)</td><td align="center" valign="top" charoff="50">&#x000a0;</td></tr><tr><td align="left" valign="top" charoff="50">Age</td><td align="center" valign="top" charoff="50">&#x000a0;</td><td align="center" valign="top" charoff="50">&#x000a0;</td><td align="center" valign="top" charoff="50">&#x000a0;</td><td align="center" valign="top" charoff="50">0.73</td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;&#x02264;50 y</td><td align="center" valign="top" charoff="50">23/30 (76.7)</td><td align="center" valign="top" charoff="50">17/34 (50.0)</td><td align="center" valign="top" charoff="50">26.7 (4.1 to 49.3)</td><td align="center" valign="top" charoff="50">&#x000a0;</td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;&#x0003e;50 y</td><td align="center" valign="top" charoff="50">43/64 (67.2)</td><td align="center" valign="top" charoff="50">26/59 (44.1)</td><td align="center" valign="top" charoff="50">23.1 (6.1 to 40.2)</td><td align="center" valign="top" charoff="50">&#x000a0;</td></tr><tr><td align="left" valign="top" charoff="50">Sex</td><td align="center" valign="top" charoff="50">&#x000a0;</td><td align="center" valign="top" charoff="50">&#x000a0;</td><td align="center" valign="top" charoff="50">&#x000a0;</td><td align="center" valign="top" charoff="50">0.94</td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;Female</td><td align="center" valign="top" charoff="50">30/43 (69.8)</td><td align="center" valign="top" charoff="50">19/41 (46.3)</td><td align="center" valign="top" charoff="50">23.4 (2.9 to 44.0)</td><td align="center" valign="top" charoff="50">&#x000a0;</td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;Male</td><td align="center" valign="top" charoff="50">36/51 (70.6)</td><td align="center" valign="top" charoff="50">24/52 (46.2)</td><td align="center" valign="top" charoff="50">24.4 (6.0 to 43.0)</td><td align="center" valign="top" charoff="50">&#x000a0;</td></tr><tr><td align="left" valign="top" charoff="50">BMI</td><td align="center" valign="top" charoff="50">&#x000a0;</td><td align="center" valign="top" charoff="50">&#x000a0;</td><td align="center" valign="top" charoff="50">&#x000a0;</td><td align="center" valign="top" charoff="50">0.26</td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;&#x02264;27.0&#x02009;kg/m<sup>2</sup></td><td align="center" valign="top" charoff="50">41/54 (75.9)</td><td align="center" valign="top" charoff="50">25/52 (48.1)</td><td align="center" valign="top" charoff="50">27.9 (10.1 to 45.6)</td><td align="center" valign="top" charoff="50">&#x000a0;</td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;27.1&#x02013;30.0&#x02009;kg/m<sup>2</sup></td><td align="center" valign="top" charoff="50">15/21 (71.4)</td><td align="center" valign="top" charoff="50">12/29 (41.4)</td><td align="center" valign="top" charoff="50">30.1 (3.7 to 56.4)</td><td align="center" valign="top" charoff="50">&#x000a0;</td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;&#x0003e;30.0&#x02009;kg/m<sup>2</sup></td><td align="center" valign="top" charoff="50">10/19 (52.6)</td><td align="center" valign="top" charoff="50">6/12 (50.0)</td><td align="center" valign="top" charoff="50">2.6 (&#x02212;33.5 to 38.8)</td><td align="center" valign="top" charoff="50">&#x000a0;</td></tr><tr><td align="left" valign="top" charoff="50">APRI score</td><td align="center" valign="top" charoff="50">&#x000a0;</td><td align="center" valign="top" charoff="50">&#x000a0;</td><td align="center" valign="top" charoff="50">&#x000a0;</td><td align="center" valign="top" charoff="50">0.83</td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;&#x02264;1.50</td><td align="center" valign="top" charoff="50">38/56 (67.9)</td><td align="center" valign="top" charoff="50">23/50 (46.0)</td><td align="center" valign="top" charoff="50">21.9 (3.4 to 40.3)</td><td align="center" valign="top" charoff="50">&#x000a0;</td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;1.51&#x02013;2.00</td><td align="center" valign="top" charoff="50">9/12 (75.0)</td><td align="center" valign="top" charoff="50">9/21 (42.9)</td><td align="center" valign="top" charoff="50">32.1 (&#x02212;0.2 to 64.5)</td><td align="center" valign="top" charoff="50">&#x000a0;</td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;&#x0003e;2.00</td><td align="center" valign="top" charoff="50">19/26 (73.1)</td><td align="center" valign="top" charoff="50">11/22 (50.0)</td><td align="center" valign="top" charoff="50">23.1 (&#x02212;3.9 to 50.0)</td><td align="center" valign="top" charoff="50">&#x000a0;</td></tr><tr><td align="left" valign="top" charoff="50">RBV cumulative exposure</td><td align="center" valign="top" charoff="50">&#x000a0;</td><td align="center" valign="top" charoff="50">&#x000a0;</td><td align="center" valign="top" charoff="50">&#x000a0;</td><td align="center" valign="top" charoff="50">0.48</td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;&#x0003c;60%</td><td align="center" valign="top" charoff="50">7/18 (38.9)</td><td align="center" valign="top" charoff="50">1/15 (6.7)</td><td align="center" valign="top" charoff="50">32.2 (6.4 to 58.4)</td><td align="center" valign="top" charoff="50">&#x000a0;</td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;60%&#x02013;80%</td><td align="center" valign="top" charoff="50">15/19 (77.8)</td><td align="center" valign="top" charoff="50">9/20 (45.0)</td><td align="center" valign="top" charoff="50">34.0 (5.5 to 62.4)</td><td align="center" valign="top" charoff="50">&#x000a0;</td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;&#x02265;80%</td><td align="center" valign="top" charoff="50">44/57 (77.2)</td><td align="center" valign="top" charoff="50">33/58 (56.9)</td><td align="center" valign="top" charoff="50">20.3 (3.5 to 37.1)</td><td align="center" valign="top" charoff="50">&#x000a0;</td></tr></tbody></table><table-wrap-foot><fn id="t3-fn1"><p>RD: risk reduction, CI: confidence interval, IL: interleukin, BMI: body mass index, APRI: aspartate aminotransferase to platelet ratio index</p></fn><fn id="t3-fn2"><p><sup>*</sup>The interaction for the prespecified factors was compared by stratified Mantel-Haenszel test.</p></fn><fn id="t3-fn3"><p><sup>&#x02020;</sup>Available number of patients (%) for analysis: 88 (94%) and 84 (90%) in SD48W and SD24W arms, respectively.</p></fn></table-wrap-foot></table-wrap><table-wrap position="float" id="t4"><label>Table 4</label><caption><title>Adverse Events, Dose reduction and Treatment Discontinuation in Treated Patients <xref ref-type="fn" rid="t4-fn1">*</xref>.</title></caption><table frame="hsides" rules="groups" border="1"><colgroup><col align="left" /><col align="char" char="(" /><col align="char" char="(" /></colgroup><thead valign="bottom"><tr><th align="left" valign="top" charoff="50">Parameter</th><th align="center" valign="top" char="(" charoff="50">SD48W, N&#x02009;=&#x02009;94</th><th align="center" valign="top" char="(" charoff="50">SD24W, N&#x02009;=&#x02009;93</th></tr></thead><tbody valign="top"><tr><td colspan="3" align="left" valign="top" charoff="50">Serious AEs</td></tr><tr><td align="left" valign="top" charoff="50">All<xref ref-type="fn" rid="t4-fn2">&#x02020;</xref></td><td align="char" valign="top" char="(" charoff="50">4 (4.3)</td><td align="char" valign="top" char="(" charoff="50">3 (3.2)</td></tr><tr><td align="left" valign="top" charoff="50">Death</td><td align="char" valign="top" char="(" charoff="50">0 (0)</td><td align="char" valign="top" char="(" charoff="50">0 (0)</td></tr><tr><td align="left" valign="top" charoff="50">Treatment-related</td><td align="char" valign="top" char="(" charoff="50">3 (3.2)</td><td align="char" valign="top" char="(" charoff="50">3 (3.2)</td></tr><tr><td align="left" valign="top" charoff="50">Treatment withdrawal due to AEs</td><td align="char" valign="top" char="(" charoff="50">11 (11.7)</td><td align="char" valign="top" char="(" charoff="50">6 (6.5)</td></tr><tr><td colspan="3" align="left" valign="top" charoff="50">Dose reduction to AEs</td></tr><tr><td align="left" valign="top" charoff="50">Peginterferon</td><td align="char" valign="top" char="(" charoff="50">23 (24.5)</td><td align="char" valign="top" char="(" charoff="50">20 (21.5)</td></tr><tr><td align="left" valign="top" charoff="50">Ribavirin</td><td align="char" valign="top" char="(" charoff="50">45 (47.9)</td><td align="char" valign="top" char="(" charoff="50">35 (37.6)</td></tr><tr><td colspan="3" align="left" valign="top" charoff="50">Constitutional AEs</td></tr><tr><td align="left" valign="top" charoff="50">Flu-like symptoms</td><td align="char" valign="top" char="(" charoff="50">29 (30.9)</td><td align="char" valign="top" char="(" charoff="50">27 (29.0)</td></tr><tr><td align="left" valign="top" charoff="50">Fatigue</td><td align="char" valign="top" char="(" charoff="50">57 (60.6)</td><td align="char" valign="top" char="(" charoff="50">54 (58.1)</td></tr><tr><td align="left" valign="top" charoff="50">Headache</td><td align="char" valign="top" char="(" charoff="50">26 (27.7)</td><td align="char" valign="top" char="(" charoff="50">28 (30.1)</td></tr><tr><td align="left" valign="top" charoff="50">Insomnia</td><td align="char" valign="top" char="(" charoff="50">34 (36.2)</td><td align="char" valign="top" char="(" charoff="50">33 (35.5)</td></tr><tr><td align="left" valign="top" charoff="50">Irritability</td><td align="char" valign="top" char="(" charoff="50">11 (11.7)</td><td align="char" valign="top" char="(" charoff="50">10 (10.8)</td></tr><tr><td align="left" valign="top" charoff="50">Depression</td><td align="char" valign="top" char="(" charoff="50">14 (14.9)</td><td align="char" valign="top" char="(" charoff="50">12 (12.9)</td></tr><tr><td align="left" valign="top" charoff="50">Anorexia</td><td align="char" valign="top" char="(" charoff="50">30 (31.9)</td><td align="char" valign="top" char="(" charoff="50">27 (29.0)</td></tr><tr><td align="left" valign="top" charoff="50">Diarrhea</td><td align="char" valign="top" char="(" charoff="50">12 (12.8)</td><td align="char" valign="top" char="(" charoff="50">12 (12.9)</td></tr><tr><td align="left" valign="top" charoff="50">Constipation</td><td align="char" valign="top" char="(" charoff="50">11 (11.7)</td><td align="char" valign="top" char="(" charoff="50">8 (8.6)</td></tr><tr><td align="left" valign="top" charoff="50">Cough</td><td align="char" valign="top" char="(" charoff="50">14 (14.9)</td><td align="char" valign="top" char="(" charoff="50">15 (16.1)</td></tr><tr><td align="left" valign="top" charoff="50">Dermatitis</td><td align="char" valign="top" char="(" charoff="50">28 (29.8)</td><td align="char" valign="top" char="(" charoff="50">25 (26.9)</td></tr><tr><td align="left" valign="top" charoff="50">Injection site reaction</td><td align="char" valign="top" char="(" charoff="50">15 (16.0)</td><td align="char" valign="top" char="(" charoff="50">13 (14.0)</td></tr><tr><td align="left" valign="top" charoff="50">Hair loss/alopecia</td><td align="char" valign="top" char="(" charoff="50">25 (26.6)</td><td align="char" valign="top" char="(" charoff="50">24 (25.8)</td></tr><tr><td colspan="3" align="left" valign="top" charoff="50">Laboratory AEs<xref ref-type="fn" rid="t4-fn3">&#x02021;</xref></td></tr><tr><td align="left" valign="top" charoff="50">Anemia (week 1&#x02013;6)<xref ref-type="fn" rid="t4-fn4">&#x000a7;</xref></td><td align="char" valign="top" char="(" charoff="50">7 (7.4)</td><td align="char" valign="top" char="(" charoff="50">6 (6.5)</td></tr><tr><td align="left" valign="top" charoff="50">Hemoglobin level: 8.5&#x02013;9.9&#x02009;g/dL</td><td align="char" valign="top" char="(" charoff="50">6 (6.4)</td><td align="char" valign="top" char="(" charoff="50">5 (5.4)</td></tr><tr><td align="left" valign="top" charoff="50">Hemoglobin level: &#x0003c;8.5&#x02009;g/dL</td><td align="char" valign="top" char="(" charoff="50">1 (1.1)</td><td align="char" valign="top" char="(" charoff="50">1 (1.1)</td></tr><tr><td align="left" valign="top" charoff="50">Anemia (week 6 to end-of-treatment)<xref ref-type="fn" rid="t4-fn4">&#x000a7;</xref></td><td align="char" valign="top" char="(" charoff="50">42 (44.7)</td><td align="char" valign="top" char="(" charoff="50">32 (34.4)</td></tr><tr><td align="left" valign="top" charoff="50">Hemoglobin level: 8.5&#x02013;9.9&#x02009;g/dL</td><td align="char" valign="top" char="(" charoff="50">27 (28.7)</td><td align="char" valign="top" char="(" charoff="50">22 (23.7)</td></tr><tr><td align="left" valign="top" charoff="50">Hemoglobin level: &#x0003c;8.5&#x02009;g/dL</td><td align="char" valign="top" char="(" charoff="50">15 (16.0)</td><td align="char" valign="top" char="(" charoff="50">10 (10.8)</td></tr><tr><td align="left" valign="top" charoff="50">Neutropenia</td><td align="char" valign="top" char="(" charoff="50">17 (18.1)</td><td align="char" valign="top" char="(" charoff="50">14 (15.1)</td></tr><tr><td align="left" valign="top" charoff="50">Neutrophil count: 0.500&#x02013;0.749&#x02009;&#x000d7;&#x02009;10<sup>9</sup> cells/L</td><td align="char" valign="top" char="(" charoff="50">13 (13.8)</td><td align="char" valign="top" char="(" charoff="50">11 (11.8)</td></tr><tr><td align="left" valign="top" charoff="50">Neutrophil count: &#x0003c;0.500&#x02009;&#x000d7;&#x02009;10<sup>9</sup> cells/L</td><td align="char" valign="top" char="(" charoff="50">4 (4.3)</td><td align="char" valign="top" char="(" charoff="50">3 (3.2)</td></tr><tr><td align="left" valign="top" charoff="50">Thrombocytopenia</td><td align="char" valign="top" char="(" charoff="50">9 (9.6)</td><td align="char" valign="top" char="(" charoff="50">11 (11.8)</td></tr><tr><td align="left" valign="top" charoff="50">Platelet count: 25&#x02013;49&#x02009;&#x000d7;&#x02009;10<sup>9</sup> cells/L</td><td align="char" valign="top" char="(" charoff="50">8 (8.5)</td><td align="char" valign="top" char="(" charoff="50">10 (10.8)</td></tr><tr><td align="left" valign="top" charoff="50">Platelet count: &#x0003c;25&#x02009;&#x000d7;&#x02009;10<sup>9</sup> cells/L</td><td align="char" valign="top" char="(" charoff="50">1 (1.1)</td><td align="char" valign="top" char="(" charoff="50">1 (1.1)</td></tr><tr><td colspan="3" align="left" valign="top" charoff="50">ALT elevation</td></tr><tr><td align="left" valign="top" charoff="50">&#x0003e;2 times ULN</td><td align="char" valign="top" char="(" charoff="50">16 (17.0)</td><td align="char" valign="top" char="(" charoff="50">18 (19.4)</td></tr><tr><td align="left" valign="top" charoff="50">&#x0003e;5 times ULN</td><td align="char" valign="top" char="(" charoff="50">2 (2.1)</td><td align="char" valign="top" char="(" charoff="50">3 (3.2)</td></tr><tr><td colspan="3" align="left" valign="top" charoff="50">Total bilirubin elevation<xref ref-type="fn" rid="t4-fn5">&#x000b6;</xref></td></tr><tr><td align="left" valign="top" charoff="50">&#x0003e;2&#x02009;mg/dL</td><td align="char" valign="top" char="(" charoff="50">5 (5.3)</td><td align="char" valign="top" char="(" charoff="50">4 (4.3)</td></tr><tr><td align="left" valign="top" charoff="50">&#x0003e;5&#x02009;mg/dL</td><td align="char" valign="top" char="(" charoff="50">0 (0.0)</td><td align="char" valign="top" char="(" charoff="50">0 (0.0)</td></tr></tbody></table><table-wrap-foot><fn id="t4-fn1"><p>AE: adverse event, ALT: alanine aminotransferase, ULN: upper limit of normal.</p></fn><fn id="t4-fn2"><p><sup>*</sup>Values are numbers (percentages).</p></fn><fn id="t4-fn3"><p><sup>&#x02020;</sup>SD48W arm: spontaneous bacterial peritonitis at week 36 of treatment, cellulitis at week 20 of treatment, severe anemia with postural dizziness at week 12 of treatment (hemoglobin level: 7.1&#x02009;g/dL), and multiple myeloma at week 40 of treatment. SD24W arm: urinary tract infection at week 12 of treatment, community-acquired pneumonia at week 16 of treatment, severe anemia with postural dizziness at week 16 of treatment (hemoglobin level: 7.3&#x02009;g/dL), respectively. All except the patients developing multiple myeloma were considered treatment-related.</p></fn><fn id="t4-fn4"><p><sup>&#x02021;</sup>The grading of the laboratory AEs was shown for patients with the on-treatment nadir level.</p></fn><fn id="t4-fn5"><p><sup>&#x000a7;</sup>Anemia was defined as a nadir hemoglobin level &#x0003c;10.0&#x02009;g/dL.</p></fn><fn id="t4-fn6"><p><sup>&#x000b6;</sup>No patient with total bilirubin elevation had concomitant ALT elevation &#x0003e;5 times ULN.</p></fn></table-wrap-foot></table-wrap></floats-group>